Short answer: It can. Since 2025 every US testosterone label carries a blood pressure warning, after FDA-required 24-hour blood pressure studies found a rise across the class. In those studies, average systolic pressure rose by 1.7 to 4.9 mm Hg depending on the product. In the TRAVERSE trial, testosterone gel raised systolic pressure 1.5 mm Hg more than placebo over 3 years, with similar rates of heart attack, stroke and heart death. Labels ask for periodic blood pressure checks.
On February 28, 2025, FDA told makers of testosterone products to change their labels. It had asked for ambulatory blood pressure monitoring (ABPM) studies, in which a cuff takes readings around the clock for 24 hours, first for two products and then, in 2018, for every testosterone product. FDA says the completed studies confirmed a rise in blood pressure with all testosterone products, class-wide.
Products with a completed study now list their own numbers, and the rest got a new general warning. In the same action, FDA removed boxed-warning language about a higher risk of heart attack and stroke, based on the TRAVERSE trial. Labels updated in July 2025 carry a section called Blood Pressure Increases.
Each label reports the average change from the men's own starting 24-hour reading (systolic/diastolic, in mm Hg). These are not placebo comparisons.
| Product | Form | All men | Men already on blood pressure medicine |
|---|---|---|---|
| AndroGel 1.62% | Gel | +1.9/+1.3 after 16 weeks | +3.0/+2.2 |
| Xyosted | Weekly shot under the skin | +3.9/+1.5 after 12 weeks | +3.9/+1.3 |
| Kyzatrex | Capsule | +1.7/+0.6 at 4 months, +1.8/+0.6 at 6 months | +3.4/+0.7 at 4 months |
| Tlando | Capsule | +4.3/+1.4 after 4 months | +4.8/+1.6 |
| Jatenzo | Capsule | +4.9/+2.5 after 4 months | +5.4/+3.2 |
The Jatenzo label adds that average pressures had not leveled off by the end of its trial (section 5.4). Some men needed treatment: in the Xyosted 1-year study, 10% started or changed blood pressure medicine, and in the Jatenzo study 7.2% did (section 6.1). The Depo-Testosterone (cypionate) and generic enanthate labels have the general warning without study numbers.
TRAVERSE compared testosterone gel with placebo in men with heart disease or several heart risk factors. The labels report that mean systolic pressure rose 1.0 mm Hg on testosterone and fell 0.5 mm Hg on placebo by 36 months, a 1.5 mm Hg difference. Major heart events (heart death, non-fatal heart attack and non-fatal stroke) were similar: 7% on testosterone vs 7.3% on placebo.
The labels still say that blood pressure increases can raise heart risk over time. TRAVERSE tested a gel, so its numbers do not tell us how injections or capsules compare over 3 years. See blood clots on TRT for the clot findings from the same trial.
Every current label says to check blood pressure periodically, especially in men with high blood pressure, and that testosterone is not recommended for men whose high blood pressure is uncontrolled. The Tlando Medication Guide adds that blood pressure medicines may need to be started or adjusted, and that testosterone may need to be stopped if blood pressure cannot be controlled.
Home readings taken at the same time of day are easier to compare across months. Dose Track keeps the testosterone dose and date next to notes, so readings can be lined up with dose changes for the prescriber.
Read more on Dose Track: Xyosted side effects · Jatenzo side effects · Depo-Testosterone side effects · Low testosterone · Blood pressure